The U.S. launch of a biosimilar to AbbVie’s Humira appears to be hurting the copycat’s developer itself. After AbbVie reported a Humira U.S. sales decline of 26% in the first quarter, Amgen said its ...
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that competition for early-line use of Amgen/Pfizer's Enbrel and ...
A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results